Eutropics mission is to address the need for effective drugs for treating aggressive forms of lymphoma, leukemia and other cancers. The company’s objective is to discover and develop new cancer drugs that are targeted to non-responsive tumor types in cancer patients.
Our solution relies on proprietary compounds that are highly selective for specific proteins that, when targeted, cause cancer cells to die combined with novel, proprietary diagnostic assays that enable us to determine which patients and which cells will be susceptible to our therapeutic agents.
The company’s approach is based on the understanding that tumor cells endure everpresent death signaling due to their violation of many rules of normal cellular behavior. Consequently, in order to survive, many cancer cells become highly dependent on selected blocks to apoptosis or programmed cell death. This survival adaptation is also seen as a cellular Achilles heel, which makes them highly susceptible to therapies that are targeted to the proteins responsible for the block. Eutropics has developed proprietary assays that can determine if a cancer cell is in such a highly dependent state and identify the specific gene responsible for the dependence. The assay therefore, facilitates the development of a drug that can overcome the tumor cell’s inherent resistance to death by targeting this gene. In addition, the assay will also be used to identify patients whose tumors are most likely to be responsive to that therapeutic. The development and progression of Eutropics’ lead compounds into clinical trials will be significantly enhanced by this technology resulting in drugs that will be more specific and effective in treating the cancer.